Rapt Therapeutics
Rapt Therapeutics, headquartered in South San Francisco, develops oral therapies for inflammatory diseases and cancer, focusing on modulating the immune system through its proprietary drug discovery engine.
Company Overview
RAPT Therapeutics is a biopharmaceutical company that specializes in developing oral small molecule therapies for inflammatory diseases and cancer. The company's proprietary drug discovery and development engine focuses on identifying and advancing novel therapeutics that modulate the immune system. RAPT Therapeutics is headquartered in South San Francisco, California, and is publicly traded on the Nasdaq Global Market under the ticker symbol 'RAPT'.
Drug Candidates
RAPT Therapeutics' lead drug candidates include zelnecirnon (RPT193) and tivumecirnon (FLX475), both of which target C-C motif chemokine receptor 4 (CCR4). Zelnecirnon is currently being evaluated for its potential to treat atopic dermatitis and asthma. Tivumecirnon is in clinical trials to assess its effectiveness in treating various types of cancer. These candidates highlight the company's focus on developing targeted therapies for immune system modulation.
Clinical Trials
RAPT Therapeutics is actively conducting clinical trials for its lead drug candidates, zelnecirnon (RPT193) and tivumecirnon (FLX475). Zelnecirnon is being evaluated for its effectiveness in treating conditions like eczema and asthma, while tivumecirnon is undergoing trials for its potential in treating various cancers. These trials are crucial for advancing the company's mission to develop innovative treatments for inflammatory diseases and oncology.
History and Evolution
Originally incorporated as FLX Bio, Inc., the company rebranded to RAPT Therapeutics to better reflect its focus on immune-targeted therapeutics. Over the years, RAPT Therapeutics has leveraged its proprietary drug discovery and development engine to advance its pipeline of oral small molecule therapies, aiming to address significant unmet medical needs in the fields of inflammation and cancer.